Supplementary Table S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Authors:
- Funda Meric-BernstamFMFunda Meric-Bernstam
- Emiliano CalvoECEmiliano Calvo
- Keun Seok LeeKLKeun Seok Lee
- Victor MorenoVictor Moreno
- Yeon Hee ParkYeon Hee Park
- Sun Young RhaSRSun Young Rha
- Pavani ChalasaniPCPavani Chalasani
- Wei ZhongWZWei Zhong
- Li ZhouLZLi Zhou
- Steven Pirie-ShepherdSPSteven Pirie-Shepherd
- Abraham C.F. LeungALAbraham C.F. Leung
- Giuseppe CuriglianoGCGiuseppe Curigliano
Open Access
- 27 November 2025
- other
- Published by American Association for Cancer Research (AACR)